Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.50067
Abstract: Key Points Question Is adjuvant olaparib cost-effective in patients with early-stage breast cancer with high-risk disease and germline BRCA1/2 mutations? Findings In an economic evaluation using a Markov model, adjuvant olaparib therapy was associated with… read more here.
Keywords: breast cancer; adjuvant olaparib; germline brca1; olaparib ... See more keywords
PARP inhibition by olaparib alleviates chronic asthma‐associated remodeling features via modulating inflammasome signaling in mice
Sign Up to like & getrecommendations! Published in 2019 at "IUBMB Life"
DOI: 10.1002/iub.2048
Abstract: Despite the reported role of poly(ADP‐ribose) polymerase (PARP) in asthma inflammation, its contribution during remodeling is not clearly known. The main aim of the current investigation was to examine the potential of olaparib, a pharmacological… read more here.
Keywords: olaparib; via modulating; inflammasome signaling; chronic asthma ... See more keywords
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel
Sign Up to like & getrecommendations! Published in 2020 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-020-05320-4
Abstract: Olaparib is the first poly(ADP-ribose) polymerase inhibitor approved as maintenance therapy of recurrent ovarian cancer (OC) patients with a BRCA mutation. To achieve the maximum clinical benefit, adherence to olaparib must be persistent. However, in… read more here.
Keywords: real world; sharing real; olaparib toxicities; management ... See more keywords
In vitro repositioning therapy with olaparib, temozolomide and oxaliplatin in glioblastoma cell lines: U118, U87, U251, H4 and human fibroblasts
Sign Up to like & getrecommendations! Published in 2025 at "Pharmacological Reports"
DOI: 10.1007/s43440-025-00783-w
Abstract: Central nervous system (CNS) tumors, including gliomas, are among the most aggressive cancers, with glioblastoma multiforme (GBM) being the most common and lethal. This study explores the potential of multidrug repositioning as a modern chemotherapy… read more here.
Keywords: cell lines; therapy; olaparib; gbm ... See more keywords
In the literature: February 2021
Sign Up to like & getrecommendations! Published in 2021 at "ESMO Open"
DOI: 10.1016/j.esmoop.2021.100061
Abstract: BRCA1 is a tumor-suppressor gene that encodes proteins involved in the repair of DNA double-strand breaks by way of the homologous recombination repair pathway. BRCA1 mutations occur in approximately 5% of breast cancer (BC) patients.… read more here.
Keywords: literature february; anti csf1r; february 2021; treatment ... See more keywords
Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.
Sign Up to like & getrecommendations! Published in 2020 at "European urology"
DOI: 10.1016/j.eururo.2020.09.024
Abstract: The PROfound trial evaluated the PARP inhibitor olaparib in metastatic castration-resistant prostate cancers harboring alterations in BRCA1/2 and ATM (cohort A) and in 12 other homologous recombination repair genes (cohort B). Olaparib led to more… read more here.
Keywords: olaparib; cohort; metastatic castration; castration resistant ... See more keywords
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Sign Up to like & getrecommendations! Published in 2024 at "British Journal of Cancer"
DOI: 10.1038/s41416-023-02567-6
Abstract: OCTOVA compared the efficacy of olaparib (O) versus weekly paclitaxel (wP) or olaparib + cediranib (O + C) in recurrent ovarian cancer (OC). The main aim of the OCTOVA trial was to determine the progression-free survival (PFS)… read more here.
Keywords: cancer; platinum resistant; olaparib cediranib; olaparib ... See more keywords
In vitro assessment of the roles of drug transporters in the disposition and drug–drug interaction potential of olaparib
Sign Up to like & getrecommendations! Published in 2017 at "Xenobiotica"
DOI: 10.1080/00498254.2016.1241449
Abstract: Abstract 1. In vitro assessments were conducted to examine interactions between olaparib (a potent oral inhibitor of poly[ADP-ribose] polymerase) and drug transporters. 2. Olaparib showed inhibition of the hepatic drug uptake transporters OATP1B1 (IC50 values of 20.3 μM… read more here.
Keywords: limited inhibition; inhibition; drug; olaparib ... See more keywords
Olaparib, a clinically used poly(ADP-ribose) polymerase inhibitor protects against oxidant-induced cardiac myocyte death in vitro and improves cardiac contractility during early phase after heart transplantation in a rat model in vivo.
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Pharmacology"
DOI: 10.1111/bph.13983
Abstract: Background and purpose Olaparib, rucaparib and niraparib, potent inhibitors of poly(ADP-ribose) polymerase (PARP) have recently been approved for human use for oncological indications. Considering the previously demonstrated role of PARP in various forms of acute… read more here.
Keywords: heart; olaparib; model; transplantation ... See more keywords
PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.14929
Abstract: Radioresistance causes a major problem for improvement of outcomes of patients treated with radiation. Targeting for DNA repair deficient mechanisms is a hallmark of sensitization to resistance. We tested whether Olaparib, a (poly) ADP‐ribose polymerase… read more here.
Keywords: fadu cells; fadu; parp inhibitor; olaparib ... See more keywords
Electrochemical and Theoretical Investigations on the Binding of Anticancer Drug Olaparib to Human Serum Albumin
Sign Up to like & getrecommendations! Published in 2024 at "Journal of The Electrochemical Society"
DOI: 10.1149/1945-7111/ad590d
Abstract: This article explores the interaction between Olaparib (OLA), an anticancer drug, and human serum albumin (HSA) on a glassy carbon electrode using cyclic voltammetry and differential pulse voltammetry methods. The study investigates the alterations in… read more here.
Keywords: anticancer drug; olaparib; drug; human serum ... See more keywords